Georgia Erbez is a Managing Director and founded Beal Advisors in 2008.  Georgia has over 20 years experience in Investment Banking, and has focused on providing comprehensive investment banking services solely to life sciences companies for over 12 years.  Georgia has experience across a broad array of transactions, including private placements, IPOs, follow-ons, PIPEs, registered directs, convertible debt and merger and acquisition advisory services.  From 2005 to 2008, Georgia was a Senior Vice President in the life sciences investment banking group at Jefferies & Co. From 1998 to 2002 she was with the health care investment banking group at Cowen and Co., most recently as Director.  From 1997 to 1998, Georgia was an Associate with the investment banking group at Hambrecht & Quist and focused on health care services and life sciences companies.  Georgia began her career in 1989 with the investment banking group at Alex. Brown & Sons where she focused on life sciences, medical technology and health care services companies. Georgia has completed over 70 financing and merger transactions in the health care industry valued at over $7.0 billion. She received her B.A. in International Relations with an emphasis in Economics from the University of California at Davis in 1989.

Georgia focuses on mergers and acquistions, asset sales and purchases, strategic advisory, and business development and licensing for biotechnology and medical device companies in all therapeutic categories.

Jeffrey Rona is a Managing Director at Beal Advisors.  Jeff has over 20 years of experience in corporate finance, as both an investment banker and as the senior financial officer for development stage life sciences companies.

As a senior financial executive, Jeff has raised over $300 million of capital, completed two liquidity events and negotiated several licensing agreements.  From 2006-2011, Jeff was Chief Business Officer for GlobeImmune, Inc., and successful raised approximately $65 million of private capital for the company.  In 2009, he completed a broad oncology partnership with Celgene, Inc. that brought $40 million of capital into the Company and included the potential for downstream milestones and royalties of over $500 million.  Prior to GlobeImmune, Jeff was the CFO of AlgoRx Pharmaceuticals, where he successfully raised $65 million of private equity and completed the sale of the Company to Corgentech, Inc.  Jeff also raised approximately $130 million while with Antigenics, including a $72 million IPO.

As an investment banker, Jeff provided services to clients in a wide range of industries, including Healthcare, General Industrial, Real Estate, Lodging and Gaming.  At UBS, Jeff was involved in the execution of over $2 billion in transactions, including M&A, capital raising (debt and equity) and restructurings.  Earlier in his career at Coopers & Lybrand Securities, Jeff was responsible for the execution of capital raising and multiple cross-border M&A transactions.  Jeff started his career at Coopers & Lybrand in the Tax Department.  He has a B.S. in Accounting from Case Western Reserve University.